Found: 3
Select item for more details and to access through your institution.
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 5, p. 1099, doi. 10.1007/s13555-023-00913-3
- By:
- Publication type:
- Article
Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 2, p. 595, doi. 10.1007/s13555-022-00876-x
- By:
- Publication type:
- Article
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 561, doi. 10.1007/s13555-021-00679-6
- By:
- Publication type:
- Article